Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.

This small retrospective study analyzed the efficacy and safety of rituximab in adults with steroid-dependent minimal change disease. Of the seventeen relapsing steroid-dependent patients treated with rituximab, eleven had no relapses with nine being able to come off all other drugs during the mean 29.5 month follow-up period. This sets the stage for a prospective randomized controlled trial. : A Randomized Trial to Assess the Impact of Early Steroid Withdrawal on Growth in Pediatric Renal Transplantation: The TWIST Study Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Nephrology Glomerulonephritis Source Type: research